Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of NSSM are...

Full description

Saved in:

Bibliographic Details
Published in:	Npj genomic medicine Vol. 6; no. 1; p. 23
Main Authors:	Masood, Ashiq, Christ, Trevor, Asif, Samia, Rajakumar, Priya, Gustafson, Beth A., Shune, Leyla O., Salahudeen, Ameen, Nedvad, Drew, Nanua, Suparna, Paner, Agne, Kuzel, Timothy M., Levy, Mia, Subramanian, Janakiraman, Raza, Shahzad
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 17-03-2021 Nature Publishing Group Nature Portfolio
Subjects:	631/67/69 692/4017 Bioinformatics Biomedical and Life Sciences Biomedicine Brain cancer Case Report Gene Function Gene Therapy Human Genetics Internal Medicine Metastasis Multiple myeloma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Non-secretory multiple myeloma (NSMM) constitutes a distinct entity of multiple myeloma characterized by the absence of detectable monoclonal protein and rarely an absence of free light chains in the serum and urine. Given its rarity, the genomic landscape, clinical course, and prognosis of NSSM are not well characterized. Here, we report a case of a patient with relapsed and refractory NSMM with brain metastasis harboring a TFG-ALK fusion showing a dramatic and durable (over two years) response to commercially available anaplastic lymphoma kinase (ALK) inhibitors. The case emphasizes the beneficial role of molecular profiling in this target-poor disease.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2056-7944 2056-7944
DOI:	10.1038/s41525-021-00186-9